Long-Acting Injectable HIV PrEP PROs

Starting soon

Conditions studied: HIV Pre-exposure Prophylaxis

In brief

The goal of this observational study is to learn about the real world effectiveness, patient satisfaction and clinical outcomes of LAI PrEP with lenacapavir (LEN) versus cabotegravir (CAB) through surveys and interviews. Participants receiving or initiating LAI PrEP part of their regular medical care will complete surveys and interviews at three study visits over the course of 12 months.

Key facts

Study ID

NCT07379658

Run by

Anupama Raghuram MD

People needed

128

Starts

2026-01-15

Expected to finish

2028-01-01

Last updated by the study team

2026-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18 and older
• Deemed eligible for HIV PrEP per healthcare provider
• Receiving or initiating LAI PrEP, defined as:
• Current use of CAB or LEN LAI PrEP at study entry
• Initiation of either CAB or LEN LAI PrEP within 30 days of study enrollment
• Receiving PrEP services in Louisville, KY
• Able to provide informed consent and complete study assessments

You may not qualify if…

• HIV diagnosis prior to enrollment
• Currently on oral PrEP with no plans to switch to LAI PrEP
• Hypersensitivities to LEN or CAB
• Pregnant or planning to become pregnant
• PI discretion

Where it is running

• Norton Healthcare — Louisville, Kentucky, United States
• University of Louisville, School of Public Health and Information Sciences — Louisville, Kentucky, United States
• University of Louisville, Kent School of Social Work — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.